Mankind Pharma Approves Acquisition of 70% Stake in Armed Cell Therapeutics
Mankind Pharma Ltd 路 Others (Uncategorized) 路 16 Oct 2026, 12:53 am
Mankind Pharma Approves Acquisition of 70% Stake in Armed Cell Therapeutics Mankind Pharma approved an additional investment of up to EUR 45Mn in wholly owned subsidiary Mankind Pharma (Netherlands) B.V., raising its investment limit to EUR 50Mn. The subsidiary will acquire a 70% stake in Belgium-based biotech Armed Cell Therapeutics B.V. (ACTx) via an all-cash consideration of EUR 48Mn payable in instalments. ACTx develops next-generation CAR-T cancer therapies, with lead clinical programs targeting non-Hodgkin lymphoma and small cell lung cancer. This strategic transaction marks Mankind's entry into advanced oncology cell therapies.
Original exchange filing (PDF)
More announcements from Mankind Pharma Ltd
- Please find attached intimation regarding change in Corporate Office Address of RTA 路 13 Nov 2026
- Please find attached Intimation of participation in the Investor Conference 路 06 Nov 2026
- Please find attached intimation regarding ESG Rating 路 05 Nov 2026
- Intimation of participation in the Investor Conference. 路 03 Nov 2026
- Please find attached transcript of the Earnings Conference Call for Q2 & H1 FY27 路 30 Oct 2026
- Please find attached intimation regarding re-affirmation/withdrawl of Credit Rating by CRISIL 路 30 Oct 2026
- In continuation of our earlier intimation dated October 22, 2026 please find attached the Investor Presentation to be made during the said Analyst / Institutional Investors meet 路 27 Oct 2026
- Please find attached link for audio recording of the Investor Conference Call held on October 26, 2026 路 27 Oct 2026
